Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA
Primary Purpose
Acne Vulgaris
Status
Active
Phase
Phase 1
Locations
Indonesia
Study Type
Interventional
Intervention
Combination Cream
Adapalene 0,1% cream
Sponsored by
About this trial
This is an interventional treatment trial for Acne Vulgaris focused on measuring combination cream, aqua posae, adjuvant therapy
Eligibility Criteria
Inclusion Criteria:
- Female aged 15 - 50 years
- Mild and moderate acne vulgaris according to IAEM and GEA.
- Patients are willing to participate in the study until it is finished.
Exclusion Criteria:
- History of allergy to dermatocosmetic products.
- Undergoing other acne therapy, medication, or invasive action in the last month.
- Pregnant or breastfeeding patients
Sites / Locations
- Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
- Rumah Sakit Umum Pusat Cipto Mangunkusumo
- Rumah Sakit Umum Daerah Dr. Moewardi
- Rumah Sakit Umum Daerah Saiful Anwar
- Rumah Sakit Umum Pusat Dr. M. Djamil
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
Combination Cream Group
Adapalene 0,1% cream
Arm Description
Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. Subjects were evaluated on day 28 and day 56.
The control group (Group 1) will use Adapalene 0.1% cream only every night. Subjects were evaluated on day 28 and day 56.
Outcomes
Primary Outcome Measures
Change of acne severity
Based on Global Acne Severity Scale (GEA Score). On a scale of 0-5, 0 indicates almost no lesions, while 5 indicates severe acne.
Change of acne severity
Based on Indonesia Acne Expert Meeting (IAEM score). The scale consists of mild, moderate, and severe.
Change of Level Of Seborrhea
The level of seborrhea is assessed subjectively by participants on a scale of 0 (minimum level) - 10 (maximum level)
Change of erythema
Based on Clinician Erythema Assessment Scale (CEA) to assess the degree and extent of erythema. The scale ranges from 0-5; 0 indicates no erythema, while 4 indicates severe erythema.
Change of quality of life
Assessed using Cardiff Acne Disability Index. Cardiff Acne Disability Index questionnaire is an instrument to measure the quality of life of acne vulgaris patients. This instrument has 5 self-answered questions by the patient (for subjects aged≥ 18 years).
Change of quality of life
Assessed using Acne-Quality of Life. Acne-QoL is an instrument consisting of 19 questions divided into 4 categories: self-perception, social relationships, emotional effects, and acne symptoms. The total score of Acne-QoL is 0-114. The higher total score for each category obtained will interpret that the quality of life of acne vulgaris patients is getting better.
Facial Analysis Examination With Janus Facial Analysis System
Assessed using the Janus Facial Analysis System®. Janus Facial Analysis System will issue data related to the patient's facial condition.
Secondary Outcome Measures
Full Information
NCT ID
NCT05497323
First Posted
August 9, 2022
Last Updated
April 5, 2023
Sponsor
Dr.dr.Irma Bernadette, SpKK (K)
1. Study Identification
Unique Protocol Identification Number
NCT05497323
Brief Title
Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA
Official Title
Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA as Adjuvant Therapy for Acne Vulgaris Mild to Moderate
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
November 15, 2022 (Actual)
Study Completion Date
May 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dr.dr.Irma Bernadette, SpKK (K)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This clinical study will compare the effectivity and safety of combination cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad, and Zinc PCA as adjuvant therapy for acne vulgaris patients. These combination cream will be tested by mild to moderate acne vulgaris patients. Participants will be female patients aged 15-50 years old and divided into three groups. The control group (Group 1) will use Adapalene 0.1% cream only every night. Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning.
Detailed Description
This study is an experimental study with a randomized controlled trial (RCT) design on mild to moderate acne vulgaris patients who met the inclusion criteria. This study will be conducted in five Dermatology and Venereology Education Centers in Indonesia located in Jakarta (Rumah Sakit Umum Pusat Nasional dr. Cipto Mangunkusumo), Jakarta (Rumah Sakit Pusat Angkatan Darat Gatot Soebroto), Padang (Rumah Sakit Umum Pusat Dr. M. Djamil), Surakarta (Rumah Sakit Umum Daerah Dr. Moewardi), and Malang (Rumah Sakit Umum Daerah Dr. Saiful Anwar). Group 1 as control group, will receive Adapalene 0.1% cream only every night. Group 2 will receive Adapalene 0.1% cream only intermittently every two nights, and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. All participants will be evaluated in day 28 and 56. Therapy evaluation will be assessed based on the Global Acne Severity Scale (GEA Score), Indonesia Acne Expert Meeting (IAEM Score), Level of Seborrhoea, Clinician Erythema Assessment Scale (CEA), facial skin analysis with Janus Skin Facial Analysis, and evaluation of the quality of life using Cardiff Acne Disability Index and Acne-Quality of Life (Acne-QoL) specifically for participants aged older than 18 years old.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
Keywords
combination cream, aqua posae, adjuvant therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
284 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Combination Cream Group
Arm Type
Experimental
Arm Description
Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning. Subjects were evaluated on day 28 and day 56.
Arm Title
Adapalene 0,1% cream
Arm Type
Other
Arm Description
The control group (Group 1) will use Adapalene 0.1% cream only every night. Subjects were evaluated on day 28 and day 56.
Intervention Type
Drug
Intervention Name(s)
Combination Cream
Other Intervention Name(s)
La Roche Posay, Effaclar Duo (+), dermocosmetic
Intervention Description
The combination cream consists of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA, were applied every morning by group 2 and group 3.
Intervention Type
Drug
Intervention Name(s)
Adapalene 0,1% cream
Other Intervention Name(s)
Evalen®, topical acne agents
Intervention Description
Adapalene 0,1 % cream were given to subjects to be applied every night in group 1 and group 3, and intermittently every two nights in group 2.
Primary Outcome Measure Information:
Title
Change of acne severity
Description
Based on Global Acne Severity Scale (GEA Score). On a scale of 0-5, 0 indicates almost no lesions, while 5 indicates severe acne.
Time Frame
re-evaluation on day 28 and day 56 of therapy
Title
Change of acne severity
Description
Based on Indonesia Acne Expert Meeting (IAEM score). The scale consists of mild, moderate, and severe.
Time Frame
re-evaluation on day 28 and day 56 of therapy
Title
Change of Level Of Seborrhea
Description
The level of seborrhea is assessed subjectively by participants on a scale of 0 (minimum level) - 10 (maximum level)
Time Frame
re-evaluation on day 28 and day 56 of therapy
Title
Change of erythema
Description
Based on Clinician Erythema Assessment Scale (CEA) to assess the degree and extent of erythema. The scale ranges from 0-5; 0 indicates no erythema, while 4 indicates severe erythema.
Time Frame
re-evaluation on day 28 and day 56 of therapy
Title
Change of quality of life
Description
Assessed using Cardiff Acne Disability Index. Cardiff Acne Disability Index questionnaire is an instrument to measure the quality of life of acne vulgaris patients. This instrument has 5 self-answered questions by the patient (for subjects aged≥ 18 years).
Time Frame
re-evaluation on day 28 and day 56 of therapy
Title
Change of quality of life
Description
Assessed using Acne-Quality of Life. Acne-QoL is an instrument consisting of 19 questions divided into 4 categories: self-perception, social relationships, emotional effects, and acne symptoms. The total score of Acne-QoL is 0-114. The higher total score for each category obtained will interpret that the quality of life of acne vulgaris patients is getting better.
Time Frame
re-evaluation on day 28 and day 56 of therapy
Title
Facial Analysis Examination With Janus Facial Analysis System
Description
Assessed using the Janus Facial Analysis System®. Janus Facial Analysis System will issue data related to the patient's facial condition.
Time Frame
re-evaluation on day 28 and day 56 of therapy
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Female aged 15 - 50 years
Mild and moderate acne vulgaris according to IAEM and GEA.
Patients are willing to participate in the study until it is finished.
Exclusion Criteria:
History of allergy to dermatocosmetic products.
Undergoing other acne therapy, medication, or invasive action in the last month.
Pregnant or breastfeeding patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Irma BS Sitohang, MD
Organizational Affiliation
Fakultas Kedokteran Universitas Indonesia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lilik Norawati, MD
Organizational Affiliation
Departemen Ilmu Kesehatan Kulit dan Kelamin Rumah Sakit Pusat Angkatan Darat Gatot Soebroto,
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Satya WY Yenny, MD
Organizational Affiliation
Departemen Ilmu Kesehatan Kulit dan Kelamin Rumah Sakit Umum Pusat Dr. M. Djamil, Padang
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Arie Kusumawardani
Organizational Affiliation
Departemen Ilmu Kesehatan Kulit dan Kelamin Rumah Sakit Umum Daerah Dr. Moewardi, Surakarta
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Sinta Murlistyarini
Organizational Affiliation
Departemen Ilmu Kesehatan Kulit dan Kelamin Rumah Sakit Umum Daerah Saiful Anwar, Malang
Official's Role
Study Director
Facility Information:
Facility Name
Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
City
Jakarta
State/Province
DKI Jakarta
ZIP/Postal Code
10410
Country
Indonesia
Facility Name
Rumah Sakit Umum Pusat Cipto Mangunkusumo
City
Jakarta
State/Province
DKI Jakarta
ZIP/Postal Code
10430
Country
Indonesia
Facility Name
Rumah Sakit Umum Daerah Dr. Moewardi
City
Surakarta
State/Province
Jawa Tengah
Country
Indonesia
Facility Name
Rumah Sakit Umum Daerah Saiful Anwar
City
Malang
State/Province
Jawa Timur
Country
Indonesia
Facility Name
Rumah Sakit Umum Pusat Dr. M. Djamil
City
Padang
State/Province
Sumatera Barat
Country
Indonesia
12. IPD Sharing Statement
Learn more about this trial
Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA
We'll reach out to this number within 24 hrs